UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(D) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 30, 2003
ANTARES PHARMA, INC.
--------------------
(Exact Name of Registrant as Specified in Charter)
Minnesota 0-20945 41-1350192
--------- ------- ----------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
707 Eagleview Boulevard, Suite 414, Exton, PA 19341
-----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (610) 458-6200
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Required FD Disclosure.
On June 5, 2003, Antares Pharma, Inc. (the "Company") announced that, by
letter dated May 30, 2003, the Listing Qualifications arm of The Nasdaq Stock
Market, Inc. notified the Company that it fails to meet certain independent
director and audit committee requirements as set forth in Nasdaq Marketplace
Rules 4350(c) and 4350(d)(2). The Company is in discussions with Nasdaq
regarding receiving a waiver on this compliance issue.
A copy of the press release issued by the Company on June 5, 2003, is
attached hereto as Exhibit 99.1
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
99.1 Press Release dated June 5, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 5, 2003
By /s/ Lawrence M. Christian
---------------------------------
Lawrence M. Christian
Chief Financial Officer
EXHIBIT INDEX
99.1 Press Release dated June 5, 2003.